CN106188081B - A kind of D-Val ring substituent norcantharidin derivative and the preparation method and application thereof - Google Patents
A kind of D-Val ring substituent norcantharidin derivative and the preparation method and application thereof Download PDFInfo
- Publication number
- CN106188081B CN106188081B CN201610544237.5A CN201610544237A CN106188081B CN 106188081 B CN106188081 B CN 106188081B CN 201610544237 A CN201610544237 A CN 201610544237A CN 106188081 B CN106188081 B CN 106188081B
- Authority
- CN
- China
- Prior art keywords
- val
- ring substituent
- substituent norcantharidin
- chromone
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 D-Val ring substituent norcantharidin derivative Chemical class 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical group C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 claims abstract description 16
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical group C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000001424 substituent group Chemical group 0.000 claims abstract description 14
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 6
- 230000008676 import Effects 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 125000003558 D-valino group Chemical group C(=O)(O)[C@@H](C(C)C)N* 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 238000003786 synthesis reaction Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- XLVXXKZBDHWNMK-UHFFFAOYSA-N N-[(6-bromochromen-4-ylidene)amino]aniline Chemical class C1(=CC=CC=C1)NN=C1C=COC2=CC=C(C=C12)Br XLVXXKZBDHWNMK-UHFFFAOYSA-N 0.000 claims description 7
- 235000019441 ethanol Nutrition 0.000 claims description 7
- 150000002240 furans Chemical class 0.000 claims description 7
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000012074 organic phase Substances 0.000 claims description 6
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 5
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims description 5
- 229940067157 phenylhydrazine Drugs 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- XVNBWGGBXOJIDR-UHFFFAOYSA-N 6-bromochromen-4-one Chemical class O1C=CC(=O)C2=CC(Br)=CC=C21 XVNBWGGBXOJIDR-UHFFFAOYSA-N 0.000 claims description 3
- 238000005698 Diels-Alder reaction Methods 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 3
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims description 3
- 229940095758 cantharidin Drugs 0.000 claims description 3
- 229930008397 cantharidin Natural products 0.000 claims description 3
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000003292 diminished effect Effects 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000002808 molecular sieve Substances 0.000 claims description 3
- 239000012265 solid product Substances 0.000 claims description 3
- 238000005292 vacuum distillation Methods 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 1
- 238000007259 addition reaction Methods 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 208000014018 liver neoplasm Diseases 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 125000003226 pyrazolyl group Chemical group 0.000 abstract description 4
- 150000004777 chromones Chemical class 0.000 abstract description 3
- 201000007270 liver cancer Diseases 0.000 abstract description 3
- 150000003217 pyrazoles Chemical class 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000001309 chloro group Chemical class Cl* 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses one kindD‑Valine ring substituent norcantharidin derivative and the preparation method and application thereof, it is characterised in that：Existed with 1,3 dipole-diople interaction methodsD‑C in valine ring substituent norcantharidin structure5And C6Position introduces pyrazole ring, is reacted with chromone derivative and imports chromone structure, synthesizes the pyrazoles containing chromone structureD‑Valine ring substituent norcantharidin derivative, the derivative have good inhibiting effect for tumor cell line, wherein having better inhibiting rate and selectivity for human liver cancer cell, are preparing antitumor drug etc., have extraordinary prospects for commercial application.
Description
Technical field：
The invention belongs to pharmaceutical technology fields, are specifically related to a kind of pyrazoles D-Val substitution containing chromone structure
Norcantharidin derivative and the preparation method and application thereof.
Background technology：
D-Val ring substituent norcantharidin, chemical structural formula are as follows：
D-Val ring substituent norcantharidin R=(R)-CH (CH3)2；
1,3- Dipolar Cycloadditions are with its good region and main selectivity and as synthesis five member ring heterocyclic compound
More active a kind of reaction in most important method, and heterocyclic drug chemical research.In recent years, since chromone is extensive
Bioactivity, anticancer, antibacterial inhibit platelet aggregation etc. and receive much attention.So either from pharmacology still from conjunction
Angled to consider, this heterocyclic compounds has very high synthesis value.
Invention content：
The first aspect of the present invention purpose is to provide a kind of D-Val ring substituent norcantharidin derivative.
The technical solution adopted by the present invention is as follows：
A kind of D-Val ring substituent norcantharidin derivative, structural formula are as follows：
In formula：R=(R)-CH (CH3)2.
The compound relevant experimental data is as follows：
Applicant it has been investigated that：It is imported on the basis of D-Val ring substituent norcantharidin introduces five yuan of pyrazole rings
The structure of chromone can change pharmacological activity.It is determined by further experiment：It is enterprising in the structure of pyrazoles using chromone derivative
Row substitution carries out structure of modification to D-Val ring substituent norcantharidin, and the pyrazoles D-Val of structure containing chromone of preparation takes
For norcantharidin derivative, there is extraordinary pharmaceutical activity.
The second aspect of the present invention purpose is to provide a kind of preparation method of D-Val ring substituent norcantharidin derivative,
It is characterized by comprising the following steps：
(1), the synthesis of dehydronorcantharidiimide element：Maleic anhydride is finely ground, be added ether, stir under room temperature to
Dissolving instills furans, is stirred at room temperature 24~48 hours, and furans occurs Diels-Alder with maleic anhydride and reacts, and is made and goes
First dehydrogenation cantharidin (compound 1)；
(2), the synthesis of D-Val ring substituent norcantharidin：
Dehydronorcantharidiimide plain 4.2 grams (25mmol) and 2.93 grams of D-Val (25mmol) are added dry through over-molecular sieve
It in 15 milliliters dry of DMF solvent, is stirred at reflux 12 hours, 60 milliliters of dilutions of ethyl acetate is added after being cooled to room temperature, are saturated chlorine
Change ammonium salt solution to wash 6 times, 30 milliliters every time, organic phase is dried with anhydrous magnesium sulfate, and filtered organic phase vacuum distillation is spin-dried for,
White solid product (compound 3) is obtained with re-crystallizing in ethyl acetate；
(3), the synthesis of 6- bromos chromone phenylhydrazone:
There is the method that the 6- bromos chromone that carboxaldehyde radicals replaces generates schiff bases with phenylhydrazine dehydration using 3, it is specific to grasp
Make：The phenylhydrazine of 2mmol is taken to be added in the flask for filling 10mL tetrahydrofurans, then boiling water bath return stirring is slowly dripped to dissolving
Ethanol solutions of the 20mL dissolved with 3 6- bromo chromones for having carboxaldehyde radicals to replace of 2mmol is added, continues boiling water bath reflux and stirs
1h is mixed, 10 drop hydrochloric acid are added dropwise, there is pale yellow precipitate appearance.Continuous boiling water bath return stirring 5h, stops water-bath, and people 20mL is added to distill
Water stirs, and pale yellow precipitate darkens, and filters to obtain the needle-shaped product of yellowish red color.It is rinsed repeatedly, is dried in vacuo with anhydrous ether
Product 6- bromo chromone phenylhydrazones (compound 4)；
(4), chromone structure is imported：
By 1mmol D-Vals ring substituent norcantharidin and 1.1mmol6- bromo chromone phenylhydrazones in 20mL ethyl alcohol, then
1.2mL toluene-sodium-sulfonchloramides are added, flow back 9 hours, after the completion of TLC detection reactions, obtains pale yellow precipitate, is filtered under diminished pressure out precipitation, precipitate
With recrystallizing methanol, product (compound 5) is obtained after vacuum drying.
Reaction of the present invention is as follows：
It is anti-swollen in preparation that the third aspect of the present invention purpose is to provide a kind of D-Val ring substituent norcantharidin derivative
Application in terms of tumor medicine.Pass through experimental verification：Above compound, for different tumor strains for example human liver cancer cell, cancer cell of oral cavity,
Stomach cancer cell, ovarian cancer cell, leukaemia cell, colon-cancer cell etc., it is inhibited, wherein for Bel7402 (human liver cancers
Cell) there is more preferably inhibiting rate and selectivity, antitumor drug can be prepared separately, can also be used as active constituent and resist with other
Tumour medicine prepares anti-tumor compositions, has extraordinary prospects for commercial application.
Beneficial effects of the present invention are as follows：
Applicant is had found by studying：It is imported on the basis of D-Val ring substituent norcantharidin introduces five yuan of pyrazole rings
There is good pharmaceutical activity through further experiment and analysis to study different heterocycles for the structure of chromone, the derivative of generation
Assemble in same molecule on being influenced caused by pharmacological activity, is gone in D-Val substitution with 1,3- dipole-diople interactions method
C in norcantharidin structure5And C6Position introduces pyrazole ring, is reacted with chromone derivative and imports chromone structure, and synthesis contains chromone structure
Pyrazoles D-Val ring substituent norcantharidin derivative, the derivative in terms of preparing antitumor drug, have it is very good
Prospects for commercial application.
Specific implementation mode：
The present invention is described further with reference to embodiments, but embodiment should not be construed as limiting the model of the present invention
It encloses.
Embodiment 1：
(1), the synthesis of dehydronorcantharidiimide element：
Maleic anhydride is finely ground, ether is added, stirring under room temperature instills furans, be stirred at room temperature 24 to dissolving
~48 hours, furans occurred Diels-Alder with maleic anhydride and reacts, and it is plain (compound 1) that dehydronorcantharidiimide is made；
(2), the synthesis of D-Val ring substituent norcantharidin：
Dehydronorcantharidiimide plain 4.2 grams (25mmol) and 2.93 grams of D-Val (25mmol) are added dry through over-molecular sieve
It in 15 milliliters dry of DMF solvent, is stirred at reflux 12 hours, 60 milliliters of dilutions of ethyl acetate is added after being cooled to room temperature, are saturated chlorine
Change ammonium salt solution to wash 6 times, 30 milliliters every time, organic phase is dried with anhydrous magnesium sulfate, and filtered organic phase vacuum distillation is spin-dried for,
White solid product (compound 3) is obtained with re-crystallizing in ethyl acetate；
(3), the synthesis of 6- bromos chromone phenylhydrazone：
The phenylhydrazine of 2mmol is taken to be added in the flask for filling 10mL tetrahydrofurans, then boiling water bath return stirring delays to dissolving
It is slow to be added dropwise to ethanol solutions of the 20mL dissolved with 3 6- bromo chromones for thering is carboxaldehyde radicals to replace of 2mmol, continue boiling water bath and returns
Stream stirring 1h is added dropwise 10 drop hydrochloric acid, there is pale yellow precipitate appearance.Continuous boiling water bath return stirring 5h, stops water-bath, adds people 20mL
Distilled water stirs, and pale yellow precipitate darkens, and filters to obtain phenylhydrazone, the needle-shaped product of yellowish red color.It is rinsed repeatedly, very with anhydrous ether
Empty dry product 6- bromo chromone phenylhydrazones (compound 4).
(4), chromone structure is imported：
By 1mmol D-Vals ring substituent norcantharidin and 1.1mmol6- bromo chromone phenylhydrazones in 20mL ethyl alcohol, then
1.2mL toluene-sodium-sulfonchloramides are added, flow back 9 hours, after the completion of TLC detection reactions, obtains pale yellow precipitate, is filtered under diminished pressure out precipitation, precipitate
With recrystallizing methanol, product (compound 5) is obtained after vacuum drying.
5 title of compound：D-Val ring substituent norcantharidin derivative；
Chemical formula：C29H23BrN3O7；
Physico-chemical parameter：Yellow crystal, yield 53.5%, m.p.115-116 DEG C；
Structural confirmation：
1H NMR(CD3OD)δ:7.32-7.16 (m, 8H, Ar-H), 6.46 (s, 1H, C=C-H), 5.16 (d, J=
9.60Hz, 1H, H5), 4.74 (d, J=17.60Hz, 1H, H4), 4.56 (d, J=17.60Hz, 1H, H1), 4.02 (d, J=
9.60Hz, 1H, H6), 3.42 (d, J=7.20Hz, 1H, H3), 3.28 (d, J=7.20Hz, 1H, H2), 2.63-2.75 (m, 1H,
), CH 0.72 (d, 3H, J=6.4Hz, CH3), 0.94 (d, 3H, J=6.4Hz, CH3)；
IR 3428 (N-C=O), 3085 (ArH), 1703 (C=O), 1541 (C=N), 1310 (C-O-C) cm-1；
m/e:604 (100.0%), 606 (97.5%)；
Anal.calcd.for C29H23BrN3O7：C,57.52；H,3.88；N,6.90.
Application Example：Antitumor activity of the test-compound to different tumor strains is detected using mtt assay.
By above-described embodiment prepare compound (5), respectively with different tumor strains (tumour cell Bel-7402, KB,
SGC7901, HO8901, HL-60, ECA109) it is experimental subjects, test compound (5) makees the external inhibition of different tumor strains
With：Experiment uses the micro enzyme reaction colorimetric method (mtt assay) of tetramethyl azo azoles salt, activity to indicate (IC with half-inhibition concentration50)。
Steps are as follows for specific experiment：
Compound 5 is dissolved with DMSO, dilute, tumour cell BeD-7402 (human liver cancer cell), KB (cancer cell of oral cavity),
SGC7901 (stomach cancer cell), HO8901 (ovarian cancer cell), HD-60 (leukaemia cell), ECA109 (colon-cancer cell) are in 96 holes
It is planted on plate into 4000/200 holes μ D/, 2 μ D of often hole addition compound, 6.0 μM, 3.0 μM, 1.5 μM, are total to by final concentration of 12.0 μM
It is same as 37 DEG C, 5%CO2It is incubated 72 hours in cell incubator, with DMSO (1%) for blank control.After 72 hours, it is added dense eventually
Degree is the MTT of 0.25mg/mD, is placed in 37 DEG C, 5%CO24 hours in cell incubator, solvent is blotted later, and 100 μ are added per hole
D DMSO measure absorbance (OD values) with enzyme linked immunological instrument at 570nm, and the data obtained is for calculating IC50Value.Various concentration
Test-compound carries out scalping with 96 orifice plates, according to the inhibiting rate of gained, calculates IC50Value, as a result see the table below.
The IC of six kinds of table 1, D-Val ring substituent norcantharidin derivative pair tumor cell lines50Value
It can be seen that by upper table data：Compound prepared by the present invention has various tumor cell strains and inhibits to make
With, wherein for HD60 (leukaemia cell) have better inhibiting rate and selectivity, can be prepared separately antitumor drug,
Active constituent can be used as to prepare anti-tumor compositions with other antitumor drugs, there is extraordinary prospects for commercial application.
Claims (4)
1. a kind of D-Val ring substituent norcantharidin derivative, structural formula are as follows：
In formula：。
2. a kind of preparation method of D-Val ring substituent norcantharidin derivative according to claim 1, feature exist
In including the following steps：Maleic anhydride is dissolved in after ether and reacts synthesis dehydronorcantharidiimide element with furans, removes first dehydrogenation
Cantharidin and D-Val reaction synthesis D-Val ring substituent norcantharidin, then use 3 6- bromines for having carboxaldehyde radicals to replace
6- bromo chromone phenylhydrazones are synthesized with phenylhydrazine dehydration for chromone, finally by D-Val ring substituent norcantharidin and 6- bromo colors
Ketone phenylhydrazone carries out dipolar addition reaction, synthesizes D-Val ring substituent norcantharidin derivative.
3. a kind of preparation method of D-Val ring substituent norcantharidin derivative according to claim 2, feature exist
In including the following steps：
（1）, dehydronorcantharidiimide element synthesis：Maleic anhydride is finely ground, ether is added, is stirred under room temperature to molten
Solution instills furans, is stirred at room temperature 24 ~ 48 hours, and furans occurs Diels-Alder with maleic anhydride and reacts, and is made and goes first
Dehydrogenation cantharidin；
（2）, D-Val ring substituent norcantharidin synthesis：
2.93 grams of 4.2 grams of dehydronorcantharidiimide element and D-Val are added in 15 milliliters of the DMF solvent dried through over-molecular sieve,
It is stirred at reflux 12 hours, 60 milliliters of ethyl acetate is added after being cooled to room temperature and dilutes, saturated ammonium chloride solution washing 6 times, every time
30 milliliters, organic phase is dried with anhydrous magnesium sulfate, and filtered organic phase vacuum distillation is spin-dried for, and is obtained with re-crystallizing in ethyl acetate white
Color solid product；
（3）, 6- bromo chromone phenylhydrazones synthesis:
The phenylhydrazine of 2mmol is taken to be added in the flask for filling 10mL tetrahydrofurans, then boiling water bath return stirring is slowly dripped to dissolving
Ethanol solutions of the 20mL dissolved with 3 6- bromo chromones for having carboxaldehyde radicals to replace of 2mmol is added, continues boiling water bath reflux and stirs
1h is mixed, 10 drop hydrochloric acid are added dropwise, there is pale yellow precipitate appearance；Continuous boiling water bath return stirring 5h, stops water-bath, and 20mL is added and steams
Distilled water stirs, and pale yellow precipitate darkens, and filters to obtain the needle-shaped product of yellowish red color；Multiple, vacuum drying is rinsed with anhydrous ether
Obtain product 6- bromo chromone phenylhydrazones；
（4）, import chromone structure：
By 1mmol D-Vals ring substituent norcantharidin and 1.1mmol 6- bromo chromone phenylhydrazones in 20mL ethyl alcohol, add
1.2mL toluene-sodium-sulfonchloramides flow back 9 hours, after the completion of TLC detection reactions, obtain pale yellow precipitate, are filtered under diminished pressure out precipitation, precipitation first
Alcohol recrystallizes, and product D-Val ring substituent norcantharidin derivative is obtained after vacuum drying.
4. a kind of D-Val ring substituent norcantharidin derivative according to claim 1 is in terms of preparing antitumor drug
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610544237.5A CN106188081B (en) | 2016-07-06 | 2016-07-06 | A kind of D-Val ring substituent norcantharidin derivative and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610544237.5A CN106188081B (en) | 2016-07-06 | 2016-07-06 | A kind of D-Val ring substituent norcantharidin derivative and the preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106188081A CN106188081A (en) | 2016-12-07 |
| CN106188081B true CN106188081B (en) | 2018-07-17 |
Family
ID=57476387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610544237.5A Active CN106188081B (en) | 2016-07-06 | 2016-07-06 | A kind of D-Val ring substituent norcantharidin derivative and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106188081B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107602578B (en) * | 2017-11-07 | 2019-07-16 | 绍兴文理学院 | A kind of preparation method and applications of the D-Val ring substituent norcantharidin derivative of the structure containing pyridazinone |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102554122A (en) * | 2012-01-29 | 2012-07-11 | 姜玉飞 | Novel modeling method for casting large-sized and ultra large-sized alloy steel track shoes |
| CN103554123A (en) * | 2013-11-15 | 2014-02-05 | 绍兴文理学院 | Chromone structure-containing pyrazole norcantharidin derivatives, and preparation method and application thereof |
| CN103896954A (en) * | 2013-11-15 | 2014-07-02 | 绍兴文理学院 | Pyrazol norcantharidin derivative as well as preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR392301A0 (en) * | 2001-03-23 | 2001-04-26 | University Of Newcastle Research Associates Limited, The | Protein phosphatase inhibitors |
-
2016
- 2016-07-06 CN CN201610544237.5A patent/CN106188081B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102554122A (en) * | 2012-01-29 | 2012-07-11 | 姜玉飞 | Novel modeling method for casting large-sized and ultra large-sized alloy steel track shoes |
| CN103554123A (en) * | 2013-11-15 | 2014-02-05 | 绍兴文理学院 | Chromone structure-containing pyrazole norcantharidin derivatives, and preparation method and application thereof |
| CN103896954A (en) * | 2013-11-15 | 2014-07-02 | 绍兴文理学院 | Pyrazol norcantharidin derivative as well as preparation method and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| Improved synthesis and characterization of L-histidine norcantharimide, a novel potent protein phosphatase 2A inhibitor;Da-Feng Chen et al.;《Journal of Chinese Pharmaceutical Sciences》;20081231;第17卷;第134-137页 * |
| Mass spectra of novel 5,6-dehydronorcantharidin derivatives substituted by aromatic amine;Deng Liping et al.;《Journal of Shaoxing University》;20090630;第29卷(第8期);第69-71,77页 * |
| 去甲基斑蝥素衍生物的合成,碘-125标记及在动物体内的分布;黄永华等;《合成化学》;19991231;第7卷(第2期);第198-201页 * |
| 抗肿瘤药物研究I : 去甲斑鳌素氨基酸衍生物的合成与抗癌活性;田少雷等;《药学学报》;19931231;第28卷(第11期);第870-875页 * |
| 新型吡唑去甲斑蝥酰亚胺衍生物的核磁共振波谱分析;邓莉平等;《绍兴文理学院学报》;20100331;第30卷(第7期);第23-28页 * |
| 新型含色酮异噁唑类去甲斑蝥衍生物的合成;黄文盈等;《绍兴文理学院学报》;20150331;第35卷(第7期);第10-13页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106188081A (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106397445B (en) | Pyrazoles N- p-bromophenyl maleimide derivatives containing chromone structure and preparation method and application | |
| CN107674083B (en) | A kind of preparation method and applications of the L-Leu ring substituent norcantharidin derivative of the structure containing pyridazinone | |
| CN106083884B (en) | A kind of D-Leu ring substituent norcantharidin derivative and the preparation method and application thereof | |
| CN106188080B (en) | A kind of D-phenylalanine ring substituent norcantharidin derivative and the preparation method and application thereof | |
| CN106083873B (en) | A kind of L-phenylalanine ring substituent norcantharidin derivative and the preparation method and application thereof | |
| CN106220642B (en) | A kind of L-Leu ring substituent norcantharidin derivative and the preparation method and application thereof | |
| CN106188081B (en) | A kind of D-Val ring substituent norcantharidin derivative and the preparation method and application thereof | |
| CN106046019B (en) | A kind of Valine ring substituent norcantharidin derivative and the preparation method and application thereof | |
| CN110183467B (en) | P-methoxyphenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN105906633B (en) | Pyrazoles N phenyl maleimide derivatives containing chromone structure and preparation method and application | |
| CN107722029B (en) | A kind of preparation method and applications of the D-Leu ring substituent norcantharidin derivative of the structure containing pyridazinone | |
| CN105859724B (en) | Rubigan 1,6a pyrrolin quinoline [3,4 c] pyrazoles 4,6 (3aH, 5H) diketone of 3 (the oxygen 4H chromones of 6 bromine 4) 1 phenyl 5 and preparation method and application | |
| CN107602578B (en) | A kind of preparation method and applications of the D-Val ring substituent norcantharidin derivative of the structure containing pyridazinone | |
| CN105906634B (en) | P-methoxyphenyl 1,6a pyrrolin quinoline [3,4 c] pyrazoles 4,6 (3aH, 5H) diketone of 3 (the oxygen 4H chromones of 6 bromine 4) 1 phenyl 5 and preparation method and application | |
| CN107674082B (en) | A kind of preparation method and applications of the D-phenylalanine ring substituent norcantharidin derivative of the structure containing pyridazinone | |
| CN107759611B (en) | A kind of preparation method and applications of the L-phenylalanine ring substituent norcantharidin derivative of the structure containing pyridazinone | |
| CN105924445B (en) | Pyrazoles N- p-nitrophenyl maleimide derivatives containing chromone structure and preparation method and application | |
| CN108727383B (en) | L-phenylalanine substituted maleimide derivative and preparation method and application thereof | |
| CN108623604B (en) | D-phenylalanine substituted maleimide derivative and preparation method and application thereof | |
| CN110105364A (en) | The rubigan substituted maleimide amine of N- containing pyrrazole structure α-terpinene cycloaddition derivative and its preparation method and application | |
| CN105906632B (en) | Pyrazoles N- p-methylphenyl maleimide derivatives containing chromone structure and preparation method and application | |
| CN109988178A (en) | The p-nitrophenyl substituted maleimide amine of N- containing pyrrazole structure α-terpinene cycloaddition derivative and its preparation method and application | |
| CN109988176A (en) | The p-bromophenyl substituted maleimide amine of N- containing pyrrazole structure α-terpinene cycloaddition derivative and its preparation method and application | |
| CN108623603A (en) | A kind of L-Leu substituted maleimide amine derivative and the preparation method and application thereof | |
| CN108707153A (en) | A kind of D-Val substituted maleimide amine derivative and the preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191128 Address after: Room 314-1, dantaihu building (Wuluo Science Park), No.9, Taihu East Road, Wuzhong District, Suzhou, Jiangsu Province Patentee after: Suzhou ruipengcheng Technology Co., Ltd Address before: 312000, No. 508 West Ring Road, Yuecheng District, Zhejiang, Shaoxing Patentee before: Shaoxing University |
|
| TR01 | Transfer of patent right |